While data from the much-anticipated FLEX Phase III study showed that ImClone Systems Inc.'s Erbitux (cetuximab) prolonged life by about five weeks for patients with non-small-cell lung cancer (NSCLC), findings from another study of the drug in colorectal cancer showed that patients with the KRAS gene mutation were unlikely to benefit from Erbitux. (BioWorld Today)